Literature DB >> 24765688

Clinicodiagnostic features of tuberculous meningitis and the role of CSF PCR in early diagnosis: a study from north-west India.

Ashok Panagariya, R K Sureka, Tarun Ralot, Bhawna Sharma, Parul Dubey.   

Abstract

The objective of this study was to study the clinical features and laboratory profile including acid fast bacillus microscopy, cerebrospinal fluid (CSF) culture and M. tuberculosis polymerase chain reaction (PCR) for an early diagnosis of tuberculous meningitis. Fifty consecutive patients, fulfilling the clinical criteria of tuberculous meningitis, were included in the study. All patients were subjected to detailed clinical and laboratory evaluation and radiological tests. CSF acid fast bacillus microscopy, culture and PCR were carried out in all and results were analysed. Majority of the patients presented with fever, headache, vomiting and signs of meningeal Irritation. Ziehl-Neelsen staining for acid-fast bacillus was positive in 4% cases, culture in 18% cases and CSF PCR for Mycobacterium tuberculosis was positive in 68%. Miliary pattern on chest x-ray was seen in 16% and CNS tuberculomas were seen in 14% cases. The CSF PCR estimation in clinically suspected cases of tuberculous meningitis may be an extremely valuable test for early diagnosis and institution of specific therapy.

Entities:  

Mesh:

Year:  2013        PMID: 24765688

Source DB:  PubMed          Journal:  J Indian Med Assoc        ISSN: 0019-5847


  3 in total

1.  Prognostic factors of tuberculous meningitis: a single-center study.

Authors:  Jin Gu; Heping Xiao; Furong Wu; Yanping Ge; Jun Ma; Wenwen Sun
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Role of multiplex polymerase chain reaction in diagnosing tubercular meningitis.

Authors:  Anupam Berwal; Kiran Chawla; Shashidhar Vishwanath; Vishnu Prasad Shenoy
Journal:  J Lab Physicians       Date:  2017 Apr-Jun

Review 3.  Microbiological diagnosis of tuberculous meningitis: Phenotype to genotype.

Authors:  Ravindra Kumar Garg
Journal:  Indian J Med Res       Date:  2019-11       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.